MBM-55

CAS No. 2083622-09-5

MBM-55( —— )

Catalog No. M26289 CAS No. 2083622-09-5

MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 326 In Stock
5MG 297 In Stock
10MG 432 In Stock
25MG 662 In Stock
50MG 849 In Stock
100MG 1144 In Stock
200MG Get Quote In Stock
500MG 2316 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MBM-55
  • Note
    Research use only, not for human use.
  • Brief Description
    MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
  • Description
    MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.(In Vitro):MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells. MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells.MBM-55 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.53, 0.84, 7.13 μM, respectively.(In Vivo):In female BALB/c nu/nu mice bearing HCT-116 xenografts, MBM-55 (20 mg/kg; i.p.) exhibits good antitumor activity and a well-tolerated dose schedule. MBM-55 (1.0 mg/kg; i.v.) shows the CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
  • In Vitro
    Cell Cycle Analysis Cell Line:HCT-116 cells Concentration:0.5, 1 μM Incubation Time:24 hours Result:Induced G2/M phase arrest and accumulation of cells with >4N content.Apoptosis Analysis Cell Line:HCT-116 cells Concentration:0.5, 1 μM Incubation Time:24 hours Result:Caused cell apoptosis in a concentration-dependent manner.
  • In Vivo
    Animal Model:Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts) Dosage:20 mg/kg Administration:Intraperitoneal injection; twice a day for 21 days Result:Significantly suppressed tumor growth.Animal Model:Male Sprague Dawley (SD) rats Dosage:1.0 mg/kg Administration:IV injection (Pharmacokinetic Analysis)Result:The CL, Vss, T1/2, AUC0-t, and AUC0-∞ values were 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    GSK-3
  • Recptor
    AChE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2083622-09-5
  • Formula Weight
    498.562
  • Molecular Formula
    C28H27FN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (250.73 mM)
  • SMILES
    CN(C)CCn1cc(cn1)-c1ccn2c(cnc2c1)-c1ccc(C(N)=O)c(OCc2cccc(F)c2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang Y, Dong Y, et al. Acephate interferes with androgen synthesis in rat immature Leydig cells. Chemosphere. 2020 Apr;245:125597.
molnova catalog
related products
  • GS87

    GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.

  • GSK-3β inhibitor 11

    GSK-3β inhibitor 11 (compound 21) is a potent glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 10.02 μM, demonstrating potential utility in neurodegenerative disease research .

  • PF-04802367

    A potent, highly selective GSK-3 inhibitor with IC50 of 2.1 nM for human GSK-3β in enzyme assays.